The research progress of pathogenesis of focal cortical dysplasia

doi:10.3877/cma.j.issn.2095-655X.2022.01.007

Abstract

Abstract:

Focal cortical dysplasia (FCD) is a malformation of cortical development highly associated with drug-refractory epilepsy. It is one of the main causes of refractory epilepsy. In the past 20 years, the relationship between FCD and drug-refractory epilepsy has been recognized. According to the classification of the International League Against Epilepsy, FCD can be divided into FCD Ⅰ (a, b, c), FCD Ⅱ (a, b) and FCD Ⅲ (a, b, c). In recent years, the pathogenesis of FCD has been proposed. The activation of PI3K-AKT-mTOR signal pathway, the effect of GATOR on mTOR, TSC gene mutation, PTKs signal pathway gene mutation, GABA receptor hypothesis, TRPC activation, inflammation and so on can lead to FCD which can cause epilepsy. The authors summarize the previous studies on the pathogenesis of FCD and explore the mechanism of refractory epilepsy caused by FCD, so as to seek new therapeutic drugs and improve the prognosis of patients with FCD.

Key words: Focal cortical dysplasia, Refractory epilepsy, Mechanism

Jie Xu, Qiubo Li, Qingxia Kong, Mingxue Zheng. The research progress of pathogenesis of focal cortical dysplasia[J]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(01): 31-35.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2022.01.007

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I01/31

References 52

[1]	Crome L．Abnormal brain structure in mental deficiency[J]．Med World，1957，86(3): 217-223.
[2]	Crino PB.mTOR: A pathogenic signaling pathway in developmental brain malformations[J]．Trends Mol Med，2011，17(12): 734-742.DOI: 10.1016/j.molmed.2011.07.008.
[3]	Jansen LA, Mirzaa GM, Ishak GE, et al. PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia[J]．Brain，2015，138(Pt 6): 1613-1628.DOI: 10.1093/brain/awv045.
[4]	Zhou J, Blundell J, Ogawa S，et al.Pharmacological inhibition of mTORC1 suppresses anatomical，cellular，and behavioral abnormalities in neural-specific Pten knock-out mice[J]．J Neurosci，2009，29(6): 1773-1783.DOI: 10.1523/JNEUROSCI.
[5]	Lin YX, Lin K, Liu XX，et al.PI3K-AKT pathway polymerase chain reaction (PCR) array analysis of epilepsy induced by type II focal cortical dysplasia[J]．Genet Mol Res，2015，14(3): 9994-10000.DOI: 10.4238/2015.
[6]	D′Gama AM, Woodworth MB, Hossain AA，et al.Somatic mutations activating the mTOR pathway in dorsal telencephalic progenitors cause a continuum of cortical dysplasias[J]．Cell Rep，2017，21(13): 3754-3766.DOI: 10.1016/j.celrep.2017.11.106.
[7]	Pelorosso C, Watrin F, Conti V，et al.Somatic double-hit in MTOR and RPS6 in hemimegalencephaly with intractable epilepsy[J]．Hum Mol Genet，2019，28(22): 3755-3765.DOI: 10.1093/hmg/ddz194.
[8]	Dawson RE, Nieto Guil AF, Robertson LJ，et al.Functional screening of GATOR1 complex variants reveals a role for mTORC1 deregulation in FCD and focal epilepsy[J]．Neurobiol Dis，2020(134): 104640.DOI: 10.1016/j.nbd.2019.104640.
[9]	Lipton JO, Sahin M．The neurology of mTOR[J]．Neuron，2014，84(2): 275-291.DOI: 10.1016/j.neuron.2014.09.034.
[10]	Meng XF, Yu JT, Song JH, et al. Role of the mTOR signaling pathway in epilepsy[J]．J Neurol Sci，2013，332(1-2): 4-15.DOI: 10.1016/j.jns.2013.05.029.
[11]	Baulac S．mTOR signaling pathway genes in focal epilepsies[J]．Prog Brain Res，2016(226): 61-79.DOI: 10.1016/bs.pbr.2016.04.013.
[12]	Weckhuysen S, Marsan E, Lambrecq V, et al. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia[J]．Epilepsia，2016，57(6): 994-1003.DOI: 10.1111/epi.13391.
[13]	Iffland PH 2nd, Carson V, Bordey A，et al.GATORopathies：the role of amino acid regulatory gene mutations in epilepsy and cortical malformations[J]．Epilepsia，2019，60(11): 2163-2173.DOI: 10.1111/epi.16370.
[14]	Dibbens LM, de Vries B, Donatello S，et al.Mutations in DEPDC5 cause familial focal epilepsy with variable foci[J]．Nat Genet，2013，45(5): 546-551.DOI: 10.1038/ng.2599.
[15]	Scheffer IE, Heron SE, Regan BM，et al.Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations[J]．Ann Neurol，2014，75(5): 782-787.DOI: 10.1002/ana.24126.
[16]	Ricos MG, Hodgson BL, Pippucci T，et al.Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy[J]．Ann Neurol，2016，79(1): 120-131.DOI: 10.1002/ana.24547.
[17]	Baldassari S, Picard F, Verbeek NE，et al.Correction: the landscape of epilepsy-related GATOR1 variants[J]．Genet Med，2019，21(8): 1896.DOI: 10.1038/s41436-018-0325-9.
[18]	Sim JC, Scerri T, Fanjul-Fernández M, et al. Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3[J]．Ann Neurol，2016，79(1): 132-137.DOI: 10.1002/ana.24502.
[19]	Scerri T, Riseley JR, Gillies G，et al.Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5[J]．Ann Clin Transl Neurol，2015，2(5): 575-580.DOI: 10.1002/acn3.191.
[20]	Crino PB.mTOR signaling in epilepsy：insights from malformations of cortical development[J]．Cold Spring Harb Perspect Med，2015，5(4): a022442.DOI: 10.1101/cshperspect.
[21]	Nguyen LH, Mahadeo T, Bordey A. mTOR hyperactivity levels influence the severity of epilepsy and associated neuropathology in an experimental model of tuberous sclerosis complex and focal cortical dysplasia[J]．J Neurosci，2019，39(14): 2762-2773.DOI: 10.1523/JNEUROSCI.2260-18.2019.
[22]	Kumari K, Sharma MC, Kakkar A，et al.mTOR pathway activation in focal cortical dysplasia[J]．Ann Diagn Pathol，2020(46): 151523.DOI: 10.1016/j.anndiagpath.2020.151523.
[23]	Lim JS, Gopalappa R, Kim SH，et al.Somatic mutations in TSC1 and TSC2 cause focal cortical dysplasia[J]．Am J Hum Genet，2017，100(3): 454-472.DOI: 10.1016/j.ajhg.2017.01.030.
[24]	Kotulska K, Jurkiewicz E, Domańska-Pakieła D，et al.Epilepsy in newborns with tuberous sclerosis complex[J]．Eur J Paediatr Neurol，2014，18(6): 714-721.DOI: 10.1016/j.ejpn.2014.06.009.
[25]	Hoelz H, Coppenrath E, Hoertnagel K, et al. Childhood-onset epileptic encephalopathy associated with isolated focal cortical dysplasia and a novel TSC1 germline mutation[J]．Clin EEG Neurosci，2018，49(3): 187-191.DOI: 10.1177/1550059417697841.
[26]	Dixit AB, Sharma D, Tripathi M，et al.Genome-wide DNA methylation and RNAseq analyses identify aberrant signalling pathways in focal cortical dysplasia (FCD) type II[J]．Sci Rep，2018，8(1): 17976.DOI: 10.1038/s41598-018-35892-5.
[27]	Parker WE, Orlova KA, Heuer GG, et al. Enhanced epidermal growth factor，hepatocyte growth factor，and vascular endothelial growth factor expression in tuberous sclerosis complex[J]．Am J Pathol，2011，178(1): 296-305.DOI: 10.1016/j.ajpath.2010.11.031.
[28]	Xu B, Michalski B, Racine RJ，et al.Continuous infusion of neurotrophin-3 triggers sprouting，decreases the levels of TrkA and TrkC，and inhibits epileptogenesis and activity-dependent axonal growth in adult rats[J]．Neuroscience，2002，115(4): 1295-1308.DOI: 10.1016/s0306-4522(02)00384-6.
[29]	Pönniö T, Conneely OM.nor-1 regulates hippocampal axon guidance，pyramidal cell survival，and seizure susceptibility[J]．Mol Cell Biol，2004，24(20): 9070-9078.DOI: 10.1128/MCB.24.20.9070-9078.2004.
[30]	Kuchukhidze G, Wieselthaler-Hölzl A, Drexel M，et al.Calcium-binding proteins in focal cortical dysplasia[J]．Epilepsia，2015，56(8): 1207-1216.DOI: 10.1111/epi.13053.
[31]	Blauwblomme T, Dossi E, Pellegrino C，et al.Gamma-aminobutyric acidergic transmission underlies interictal epileptogenicity in pediatric focal cortical dysplasia[J]．Ann Neurol，2019，85(2): 204-217.DOI: 10.1002/ana.25403.
[32]	Talos DM, Sun H, Kosaras B，et al.Altered inhibition in tuberous sclerosis and type Ⅱb cortical dysplasia[J]．Ann Neurol，2012，71(4): 539-551.DOI: 10.1002/ana.22696.
[33]	Sakakibara T, Sukigara S, Otsuki T，et al.Imbalance of interneuron distribution between neocortex and basal ganglia: consideration of epileptogenesis of focal cortical dysplasia[J]．J Neurol Sci，2012，323(1-2): 128-133.DOI: 10.1016/j.jns.2012.08.035.
[34]	Han P, Welsh CT, Smith MT，et al.Complex patterns of GABAergic neuronal deficiency and type 2 potassium-chloride cotransporter immaturity in human focal cortical dysplasia[J]．J Neuropathol Exp Neurol，2019，78(4): 365-372.DOI: 10.1093/jnen/nlz009.
[35]	Zhong S, Zhao Z, Xie W，et al.GABAergic Interneuron and neurotransmission are mTOR-dependently disturbed in experimental focal cortical dysplasia[J]．Mol Neurobiol，2021，58(1): 156-169.DOI: 10.1007/s12035-020-02086-y.
[36]	Birnbaumer L．The TRPC class of ion channels: a critical review of their roles in slow，sustained increases in intracellular Ca(2+) concentrations[J]．Annu Rev Pharmacol Toxicol，2009(49): 395-426.DOI: 10.1146/annurev.pharmtox.48.113006.094928.
[37]	Vazquez G, Wedel BJ, Aziz O，et al.The mammalian TRPC cation channels[J]．Biochim Biophys Acta，2004，1742(1-3): 21-36.DOI: 10.1016/j.bbamcr.2004.08.015.
[38]	Bon RS, Beech DJ.In pursuit of small molecule chemistry for calcium-permeable non-selective TRPC channels-mirage or pot of gold？[J]．Br J Pharmacol，2013，170(3): 459-474.DOI: 10.1111/bph.12274.
[39]	Li HS, Xu XZ, Montell C．Activation of a TRPC3-dependent cation current through the neurotrophin BDNF[J]．Neuron，1999，24(1): 261-273.DOI: 10.1016/s0896-6273(00)80838-7.
[40]	Kato AS, Knierman MD, Siuda ER，et al.Glutamate receptor δ2 associates with metabotropic glutamate receptor 1 (mGluR1), protein kinase Cγ，and canonical transient receptor potential 3 and regulates mGluR1-mediated synaptic transmission in cerebellar Purkinje neurons[J]．J Neurosci，2012，32(44): 15296-15308.DOI: 10.1523/JNEUROSCI.0705-12.2012.
[41]	Lauderdale K, Murphy T, Tung T，et al.Osmotic edema rapidly increases neuronal excitability through activation of NMDA receptor-dependent slow inward currents in juvenile and adult hippocampus[J]．ASN Neuro，2015，7(5): 1759091415605115.DOI: 10.1177/1759091415605115.
[42]	Sun D, Ma H, Ma J，et al.Canonical transient receptor potential channel 3 contributes to febrile seizure inducing neuronal cell death and neuroinflammation[J]．Cell Mol Neurobiol，2018，38(6): 1215-1226.DOI: 10.1007/s10571-018-0586-5.
[43]	Liang C, Chen X, Zhang CQ，et al.Expression of TRPC3 in cortical lesions from patients with focal cortical dysplasia[J]．Neurosci Lett，2020(724): 134880.DOI: 10.1016/j.neulet.2020.134880.
[44]	Zheng DH, Guo W, Sun FJ，et al.Expression of TRPC6 and BDNF in cortical lesions from patients with focal cortical dysplasia[J]．J Neuropathol Exp Neurol，2016，75(8): 718-730.DOI: 10.1093/jnen/nlw044.
[45]	Aronica E, Crino PB.Inflammation in epilepsy: clinical observations[J]．Epilepsia，2011，52 (Suppl 3): 26-32.DOI: 10.1111/j.1528-1167.2011.03033.x.
[46]	Zimmer TS, Ciriminna G, Arena A，et al.Chronic activation of anti-oxidant pathways and iron accumulation in epileptogenic malformations[J]．Neuropathol Appl Neurobiol，2020，46(6): 546-563.DOI: 10.1111/nan.12596.
[47]	Arena A, Zimmer TS, van Scheppingen J，et al.Oxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependence[J]．Brain Pathol，2019，29(3): 351-365.DOI: 10.1111/bpa.12661.
[48]	Zhang Z, Liu Q, Liu M，et al. Upregulation of HMGB1-TLR4 inflammatory pathway in focal cortical dysplasia type Ⅱ[J]．J Neuroinflammation，2018，15(1): 27.DOI: 10.1186/s12974-018-1078-8.
[49]	Srivastava A, Dixit AB, Paul D, et al. Comparative analysis of cytokine/chemokine regulatory networks in patients with hippocampal sclerosis (HS) and focal cortical dysplasia (FCD)[J]．Sci Rep，2017，7(1): 15904.DOI: 10.1038/s41598-017-16041-w.
[50]	Jung T, Grune T．The proteasome and the degradation of oxidized proteins：part I-structure of proteasomes[J]．Redox Biol，2013，1(1): 178-182.DOI: 10.1016/j.redox.2013.01.004.
[51]	van Scheppingen J, Broekaart DW, Scholl T，et al.Dysregulation of the (immuno)proteasome pathway in malformations of cortical development[J]．J Neuroinflammation，2016，13(1): 202.DOI: 10.1186/s12974-016-0662-z.
[52]	He JJ, Li S, Shu HF，et al.The interleukin 17 system in cortical lesions in focal cortical dysplasias[J]．J Neuropathol Exp Neurol，2013，72(2): 152-163.DOI: 10.1097/NEN.0b013e318281262e.

Please choose a citation manager

Content to export